Targeting the cancer stroma with a fibroblast activation protein-activated promelittin protoxin
Open Access
- 1 May 2009
- journal article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 8 (5), 1378-1386
- https://doi.org/10.1158/1535-7163.mct-08-1170
Abstract
Fibroblast-Activation Protein-α (FAP) is a membrane-bound serine protease that is expressed on the surface of reactive stromal fibroblasts present within the majority of human epithelial tumors but is not expressed by normal tissues. FAP is a postprolyl peptidase that differs from other dipeptidyl prolyl peptidases such as diprolylpeptidase 4 in that it also has gelatinase and collagenase endopeptidase activity. Therefore, FAP represents a potential pan-tumor target whose enzymatic activity can be exploited for the intratumoral activation of prodrugs and protoxins. To evaluate FAP as a tumor-specific target, putative FAP-selective peptide protoxins were constructed through modification of the prodomain of melittin, a 26 amino acid amphipathic cytolytic peptide that is the main toxic component in the venom of the common European honeybee Apis milefera. Melittin is synthesized as promelittin, containing a 22 amino acid NH2-terminal prodomain rich in the amino acids proline and alanine. In this study, peptides containing truncated melittin prodomain sequences were tested on erythrocytes to determine the optimal prodomain length for inhibiting cytolytic activity. Once optimized, modified promelittin peptides were generated in which previously identified FAP substrate sequences were introduced into the prodomain. Peptide protoxins were identified that were efficiently activated by FAP and selectively toxic to FAP-expressing cell lines with an IC50 value in the low micromolar range that is similar to melittin. Intratumoral injection of an FAP-activated protoxin produced significant lysis and growth inhibition of human breast and prostate cancer xenografts with minimal toxicity to the host animal. [Mol Cancer Ther 2009;8(5):1378–86]Keywords
This publication has 37 references indexed in Scilit:
- Identification of novel vascular markers through gene expression profiling of tumor-derived endotheliumBMC Genomics, 2008
- Fibroblast Activation Protein Peptide Substrates Identified from Human Collagen I Derived Gelatin Cleavage SitesBiochemistry, 2007
- A Prostate-Specific Antigen-Activated Channel-Forming Toxin as Therapy for Prostatic DiseaseJNCI Journal of the National Cancer Institute, 2007
- A Dimeric Peptide That Binds Selectively to Prostate-Specific Membrane Antigen and Inhibits its Enzymatic ActivityCancer Research, 2006
- Structural and Kinetic Analysis of the Substrate Specificity of Human Fibroblast Activation Protein αJournal of Biological Chemistry, 2005
- Stromal Antigen Targeting by a Humanised Monoclonal Antibody: An Early Phase II Trial of Sibrotuzumab in Patients with Metastatic Colorectal CancerOncology Research and Treatment, 2003
- Stromal expression of fibroblast activation protein/seprase, a cell membrane serine proteinase and gelatinase, is associated with longer survival in patients with invasive ductal carcinoma of breastInternational Journal of Cancer, 2001
- Identification of the 170-kDa Melanoma Membrane-bound Gelatinase (Seprase) as a Serine Integral Membrane ProteaseJournal of Biological Chemistry, 1997
- A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomasNature, 1990
- Tumors: Wounds That Do Not HealNew England Journal of Medicine, 1986